Search

The article offers information on a study related to the epidemiology of Recombinant urate oxidase (rasburicase) use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. It notes the use of Pediatric Health Information System database (PHIS) for the study which include demographics, diagnosis codes and daily resource utilization data.

Despite the importance of adverse event (AE) reporting, AEs are under-reported on clinical trials. We hypothesized that electronic medical record (EMR) data can ascertain laboratory-based AEs more accurately than those ascertained manually. EMR data on 12 AEs for patients enrolled on two Children's Oncology Group (COG) trials at one institution were extracted, processed and graded. When compared to gold standard chart data, COG AE report sensitivity and positive predictive values (PPV) were 0-21·1% and 20-100%, respectively. EMR sensitivity and PPV were >98·2% for all AEs. These results demonstrate that EMR-based AE ascertainment and grading substantially improves laboratory AE reporting accuracy. [ABSTRACT FROM AUTHOR]